These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 34234609)

  • 1. Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma.
    Neupane K; Wahab A; Masood A; Faraz T; Bahram S; Ehsan H; Hannan A; Anwer F
    J Blood Med; 2021; 12():529-550. PubMed ID: 34234609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma.
    Prawitz T; Popat R; Suvannasankha A; Sarri G; Hughes R; Wang F; Hogea C; Ferrante SA; Gorsh B; Willson J; Kapetanakis V
    Adv Ther; 2021 Nov; 38(11):5501-5518. PubMed ID: 34561812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma.
    Becnel MR; Lee HC
    Ther Adv Hematol; 2020; 11():2040620720979813. PubMed ID: 33403093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma.
    Wahab A; Rafae A; Mushtaq K; Masood A; Ehsan H; Khakwani M; Khan A
    Front Oncol; 2021; 11():678634. PubMed ID: 34046363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matching-adjusted indirect comparison of talquetamab vs selinexor-dexamethasone and vs belantamab mafodotin in patients with relapsed/refractory multiple myeloma.
    Reece D; Diels J; Van Sanden S; Pei L; Ammann E; Heuck C; Kane C; Londhe A; Peterson S; Chari A
    Curr Med Res Opin; 2024 Oct; 40(10):1769-1783. PubMed ID: 39226081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis.
    Nikolaou A; Ambavane A; Shah A; Ma W; Tosh J; Kapetanakis V; Willson J; Wang F; Hogea C; Gorsh B; Gutierrez B; Sapra S; Suvannasankha A; Samyshkin Y
    Expert Rev Hematol; 2021 Dec; 14(12):1137-1145. PubMed ID: 34465265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma.
    Suvannasankha A; Bahlis N; Trudel S; Weisel K; Koenecke C; Oriol A; Voorhees PM; Alonso AA; Callander NS; Mateos MV; Reddy N; Hakim S; LaMacchia J; Patel N; Williams D; Jewell RC; Zhou X; Gupta I; Opalinska J; Nooka AK
    Cancer; 2024 Aug; 130(15):2629-2641. PubMed ID: 38630908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma.
    McCurdy A; Visram A
    Curr Hematol Malig Rep; 2022 Dec; 17(6):306-318. PubMed ID: 36417082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor.
    Joseph NS; Tai YT; Anderson KC; Lonial S
    Clin Pharmacol; 2021; 13():169-180. PubMed ID: 34434061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
    Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Lendvai N; Sborov D; Suvannasankha A; Weisel K; Karlin L; Libby E; Arnulf B; Facon T; Hulin C; Kortüm KM; Rodríguez-Otero P; Usmani SZ; Hari P; Baz R; Quach H; Moreau P; Voorhees PM; Gupta I; Hoos A; Zhi E; Baron J; Piontek T; Lewis E; Jewell RC; Dettman EJ; Popat R; Esposti SD; Opalinska J; Richardson P; Cohen AD
    Lancet Oncol; 2020 Feb; 21(2):207-221. PubMed ID: 31859245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain.
    de la Rubia J; Alonso R; Clavero ME; Askari E; García A; Antón C; Fernández M; Escalante F; García A; Rios-Tamayo R; Conesa V; Bermúdez MA; Merchán B; Velasco AE; Blanchard MJ; Sampol A; Gainza E; Hernández PM; Alegre A
    Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.
    Offidani M; Corvatta L; Morè S; Olivieri A
    Drug Des Devel Ther; 2021; 15():2401-2415. PubMed ID: 34103900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
    Tzogani K; Penttilä K; Lähteenvuo J; Lapveteläinen T; Lopez Anglada L; Prieto C; Garcia-Ochoa B; Enzmann H; Gisselbrecht C; Delgado J; Pignatti F
    Oncologist; 2021 Jan; 26(1):70-76. PubMed ID: 33179377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
    Farooq AV; Degli Esposti S; Popat R; Thulasi P; Lonial S; Nooka AK; Jakubowiak A; Sborov D; Zaugg BE; Badros AZ; Jeng BH; Callander NS; Opalinska J; Baron J; Piontek T; Byrne J; Gupta I; Colby K
    Ophthalmol Ther; 2020 Dec; 9(4):889-911. PubMed ID: 32712806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States.
    Shah A; Tosh JC; Ambavane A; Nikolaou A; Hogea C; Samyshkin Y; Gorsh B; Maiese EM; Wang F
    Clinicoecon Outcomes Res; 2021; 13():789-800. PubMed ID: 34531667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
    Nooka AK; Cohen AD; Lee HC; Badros A; Suvannasankha A; Callander N; Abdallah AO; Trudel S; Chari A; Libby EN; Chaudhry M; Hultcrantz M; Kortüm KM; Popat R; Sborov D; Hakim S; Lewis E; Gorsh B; Bhushan B; McKeown A; Gupta I; Opalinska J; Richardson PG; Lonial S
    Cancer; 2023 Dec; 129(23):3746-3760. PubMed ID: 37622738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP).
    Alegre A; Benzo G; Alonso R; Martínez-López J; Jimenez-Ubieto A; Cuéllar C; Askari E; Prieto E; Aláez C; Aguado B; Velasco A; Krsnik I; Bocanegra A; Llorente L; Muñoz-Linares C; Morales A; Giménez E; Iglesias R; Martínez-Chamorro C; Alonso A; Jiménez-Montes C; Blanchard MJ;
    Oncol Ther; 2023 Mar; 11(1):83-96. PubMed ID: 36509945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects.
    Lassiter G; Bergeron C; Guedry R; Cucarola J; Kaye AM; Cornett EM; Kaye AD; Varrassi G; Viswanath O; Urits I
    Curr Oncol; 2021 Jan; 28(1):640-660. PubMed ID: 33494319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM).
    Lonial S; Nooka AK; Thulasi P; Badros AZ; Jeng BH; Callander NS; Potter HA; Sborov D; Zaugg BE; Popat R; Degli Esposti S; Byrne J; Opalinska J; Baron J; Piontek T; Gupta I; Dana R; Farooq AV; Colby K; Jakubowiak A
    Blood Cancer J; 2021 May; 11(5):103. PubMed ID: 34039952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study.
    Shragai T; Magen H; Lavi N; Gatt M; Trestman S; Zektser M; Ganzel C; Jarchowsky O; Berger T; Tadmor T; Leiba M; Hertzog-Tzarfaty K; Horowitz N; Shapira M; Varssano D; Berger Y; Frenkel S; Krauthammer M; Avivi I; Luttwak E; Cohen YC;
    Br J Haematol; 2023 Jan; 200(1):45-53. PubMed ID: 36205375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.